Array Expects To Have Phase III MEK Inhibitor All To Itself, Without Partner Novartis

Following Novartis’ oncology deal with GSK, which included another MEK inhibitor, Array anticipates getting the asset back for itself. Novartis would be obliged to continue supporting Phase III studies, Array says, as part of a pipeline update in second-quarter earnings call.